Drug Safety Information for RIFAMPIN (Rifampin)
Safety-related Labeling Changes for RIFADIN (RIFAMPIN) Rx Drug: FDA Link
Adverse Drug Reactions for RIFAMPIN* (Rifampin)
These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).
Top 20 Adverse Effects Associated with RIFAMPIN
(reported in FDA Medwatch/FAERS Reports)
|Side Effect||# of FDA Reports|
|2||Renal failure acute||154|
|12||Aspartate aminotransferase increased||84|
|14||Alanine aminotransferase increased||83|
|19||Drug rash with eosinophilia and systemic symptoms||77|
* This side effect also appears in "Top 10 Side Effects of RIFAMPIN " in the drug's Review Summary based on AskaPatient reviews.
Top 10 Reasons for Taking RIFAMPIN
(associated with FDA Medwatch/FAERS Reports)
|Reason||# of FDA Reports|
|2||Product used for unknown indication||1105|
|9||Lymph node tuberculosis||133|
*Also a top-10 reason in AskaPatient Review Summary.
Types of Adverse Events for RIFAMPIN
Total Reports Filed with FDA: 13250
Number of FDA Adverse Event Reports by Patient Age for RIFAMPIN
Total Reports Filed with FDA: 13250*
* Reports for drugs with the same active ingredients have been aggregated in this analysis: Rifampin (Rifadin iv, Rimactane, Rifampin, Rifadin)
Charts are based on 13250 reports filed with the FDA between 2004 and June 2015.
Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.
Click to go back to search results and RIFAMPIN Reviews and Review Summary .
Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.